Amsterdam-based myTomorrows, a platform to help patients and doctors access drugs in development, has closed a €10 million funding round. The round was led by EQT Ventures and Octopus Ventures, with participation from existing investors Balderton Capital and Sofinnova Partners.
MyTomorrows was founded in 2012 and is currently active in 17 countries. The startup saw there was a problem in the way doctors and their patients could access drugs under development - rendering potentially life-saving drugs out of reach. Therefore, myTomorrows has built a platform for doctors and patients seeking information on and access to investigational drugs, and drugs that have been approved by regulators in other countries.
MyTomorrows will use this funding to invest in technologies and talent in order to continue to help regulators, doctors and drug developers with the complex processes of providing access to investigational drugs for patients facing unmet medical needs.
“We are delighted to have attracted backing from investors whose contribution will be well beyond simply finances," said founder CEO Ronald Brus in a statement.
“myTomorrows is a great fit for EQT Ventures," said Kees Koolen, founding partner at EQT Ventures in a statement. "It has the opportunity to genuinely disrupt an industry, and solve a problem which could change many people’s lives. The team has incredible drive and deep expertise across medicine, biotech and technology. In an era where information asymmetry has been removed by the internet, myTomorrows has created a digital marketplace connecting physicians with drug developers under the watchful eye of local regulators, in order to facilitate access to drugs that might otherwise be out of reach for patients who have run out of other treatment options. We look forward to supporting the team in its ambitions.”
Read more: Private Equity Wire (Press release)